RU2007141683A - Вариантная форма урат-оксидазы и ее использование - Google Patents
Вариантная форма урат-оксидазы и ее использование Download PDFInfo
- Publication number
- RU2007141683A RU2007141683A RU2007141683/13A RU2007141683A RU2007141683A RU 2007141683 A RU2007141683 A RU 2007141683A RU 2007141683/13 A RU2007141683/13 A RU 2007141683/13A RU 2007141683 A RU2007141683 A RU 2007141683A RU 2007141683 A RU2007141683 A RU 2007141683A
- Authority
- RU
- Russia
- Prior art keywords
- uricase
- amino acid
- terminal amino
- nucleic acid
- seq
- Prior art date
Links
- 108010092464 Urate Oxidase Proteins 0.000 claims abstract 39
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims abstract 16
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 12
- 108020004707 nucleic acids Proteins 0.000 claims abstract 10
- 102000039446 nucleic acids Human genes 0.000 claims abstract 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract 8
- 150000001413 amino acids Chemical group 0.000 claims abstract 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims abstract 4
- 239000004471 Glycine Substances 0.000 claims abstract 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000004473 Threonine Substances 0.000 claims abstract 4
- 235000004279 alanine Nutrition 0.000 claims abstract 4
- 229930182817 methionine Natural products 0.000 claims abstract 4
- 239000002773 nucleotide Substances 0.000 claims abstract 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 2
- 238000012258 culturing Methods 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 101150004298 osmB gene Proteins 0.000 claims abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Выделенная уриказа, содержащая последовательность аминокислот от положения 8 до положения 287 SEQ ID NO. 7. ! 2. Уриказа по п.1, содержащая последовательность SEQ ID NO. 8. ! 3. Уриказа по п.1, дополнительно содержащая N-концевую аминокислоту, где N-концевой аминокислотой является аланин, глицин, пролин, серин или треонин. ! 4. Уриказа по п.1, дополнительно содержащая N-концевую аминокислоту, где N-концевая аминокислота является метионином. ! 5. Выделенная уриказа, содержащая последовательность аминокислот от положения 8 до положения 287 SEQ ID NO. 12. ! 6. Уриказа по п.5, содержащая последовательность аминокислот SEQ ID NO. 13. ! 7. Уриказа по п.5, дополнительно содержащая N-концевую аминокислоту, где N-концевая аминокислота является аланином, глицином, пролином, серином или треонином. ! 8. Уриказа по п.5, дополнительно содержащая N-концевую аминокислоту, где N-концевая аминокислота является метионином. ! 9. Уриказа по п.1, где уриказа является ПЭГ-конъюгированной уриказой. ! 10. Выделенная нуклеиновая кислота, содержащая последовательность нуклеотидов, которая кодирует уриказу, выбранную из группы, состоящей из: уриказы по п.1, уриказы по п.2, уриказы по п.3, уриказы по п.5, уриказы по п.6, и уриказы по п.7. ! 11. Выделенная нуклеиновая кислота по п.10, где последовательность нуклеотидов оперативно связана с гетерологичному промотору. ! 12. Нуклеиновая кислота по п.10, где промотор является промотором osmB. ! 13. Нуклеиновокислотный вектор, содержащий нуклеиновую кислоту по п.11. ! 14. Клетка-хозяин, содержащая вектор по п.13. ! 15. Способ получения уриказы, включающий стадии культивирования клеток-хозяев по п.14 при условиях, когда последовательность нуклеиновой кислоты экспрессируе�
Claims (15)
1. Выделенная уриказа, содержащая последовательность аминокислот от положения 8 до положения 287 SEQ ID NO. 7.
2. Уриказа по п.1, содержащая последовательность SEQ ID NO. 8.
3. Уриказа по п.1, дополнительно содержащая N-концевую аминокислоту, где N-концевой аминокислотой является аланин, глицин, пролин, серин или треонин.
4. Уриказа по п.1, дополнительно содержащая N-концевую аминокислоту, где N-концевая аминокислота является метионином.
5. Выделенная уриказа, содержащая последовательность аминокислот от положения 8 до положения 287 SEQ ID NO. 12.
6. Уриказа по п.5, содержащая последовательность аминокислот SEQ ID NO. 13.
7. Уриказа по п.5, дополнительно содержащая N-концевую аминокислоту, где N-концевая аминокислота является аланином, глицином, пролином, серином или треонином.
8. Уриказа по п.5, дополнительно содержащая N-концевую аминокислоту, где N-концевая аминокислота является метионином.
9. Уриказа по п.1, где уриказа является ПЭГ-конъюгированной уриказой.
10. Выделенная нуклеиновая кислота, содержащая последовательность нуклеотидов, которая кодирует уриказу, выбранную из группы, состоящей из: уриказы по п.1, уриказы по п.2, уриказы по п.3, уриказы по п.5, уриказы по п.6, и уриказы по п.7.
11. Выделенная нуклеиновая кислота по п.10, где последовательность нуклеотидов оперативно связана с гетерологичному промотору.
12. Нуклеиновая кислота по п.10, где промотор является промотором osmB.
13. Нуклеиновокислотный вектор, содержащий нуклеиновую кислоту по п.11.
14. Клетка-хозяин, содержащая вектор по п.13.
15. Способ получения уриказы, включающий стадии культивирования клеток-хозяев по п.14 при условиях, когда последовательность нуклеиновой кислоты экспрессируется клетками-хозяевами, и выделение экспрессированной уриказы.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67054105P | 2005-04-11 | 2005-04-11 | |
| US60/670,541 | 2005-04-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007141683A true RU2007141683A (ru) | 2009-05-20 |
| RU2435847C2 RU2435847C2 (ru) | 2011-12-10 |
Family
ID=37087650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007141683/10A RU2435847C2 (ru) | 2005-04-11 | 2006-04-11 | Вариантная форма урат-оксидазы и ее использование |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US7811800B2 (ru) |
| EP (2) | EP1871877A2 (ru) |
| JP (3) | JP2008535499A (ru) |
| KR (1) | KR101304289B1 (ru) |
| CN (2) | CN102807973A (ru) |
| AU (1) | AU2006235437B2 (ru) |
| BR (1) | BRPI0612942A2 (ru) |
| CA (1) | CA2604545A1 (ru) |
| CZ (1) | CZ2007700A3 (ru) |
| HU (1) | HU229626B1 (ru) |
| IL (6) | IL186511A (ru) |
| MX (1) | MX2007012548A (ru) |
| NZ (1) | NZ562291A (ru) |
| PL (1) | PL215157B1 (ru) |
| RU (1) | RU2435847C2 (ru) |
| SG (3) | SG10201706384VA (ru) |
| TW (1) | TW200716751A (ru) |
| WO (1) | WO2006110761A2 (ru) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2316475B1 (en) * | 1998-08-06 | 2017-10-04 | Mountain View Pharmaceuticals, Inc. | Isolated tetrameric uricase |
| US8148123B2 (en) * | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| US20080159976A1 (en) * | 2005-04-11 | 2008-07-03 | Jacob Hartman | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| PL3321359T3 (pl) | 2005-04-11 | 2021-06-28 | Horizon Pharma Rheumatology Llc | Wariantowe postacie oksydazy moczanowej i ich zastosowanie |
| EP2013225B1 (en) * | 2006-04-12 | 2014-12-17 | Crealta Pharmaceuticals LLC | Purification of proteins with cationic surfactant |
| JP4890133B2 (ja) * | 2006-07-20 | 2012-03-07 | 東洋紡績株式会社 | 安定な尿酸測定試薬 |
| JP4890132B2 (ja) * | 2006-07-20 | 2012-03-07 | 東洋紡績株式会社 | ウリカーゼの比活性を向上させる方法、および比活性の向上した改変型ウリカーゼ |
| JP4890134B2 (ja) * | 2006-07-20 | 2012-03-07 | 東洋紡績株式会社 | ウリカーゼの安定性を向上させる方法、および安定性の向上した改変型ウリカーゼ |
| PL398781A1 (pl) | 2009-06-25 | 2012-11-19 | Savient Pharmaceuticals, Inc. | Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy |
| CN102051348B (zh) * | 2009-10-27 | 2012-10-03 | 重庆富进生物医药有限公司 | 人源化重组尿酸酶及其突变体 |
| WO2011127393A2 (en) | 2010-04-08 | 2011-10-13 | Georgia Tech Research Corporation | Variants of ancestral uricases and uses thereof |
| CN102634492B (zh) | 2011-02-14 | 2015-06-10 | 重庆富进生物医药有限公司 | 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用 |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| EP2986720B1 (en) | 2013-04-17 | 2017-09-06 | Council of Scientific & Industrial Research | Uricase mutants |
| CA2917671A1 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| NZ723859A (en) | 2014-03-14 | 2023-01-27 | Servier Lab | Pharmaceutical compositions of therapeutically active compounds and their uses |
| EP3294322A4 (en) | 2015-05-15 | 2018-12-12 | Medimmune, LLC | Improved uricase sequences and methods of treatment |
| CN106554948B (zh) * | 2015-09-29 | 2019-06-25 | 上海生物制品研究所有限责任公司 | 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用 |
| PT3362065T (pt) | 2015-10-15 | 2024-06-21 | Servier Lab | Terapia de combinação compreendendo ivosidenib, citarabina e daunorubicina ou idarubicina para o tratamento de leucemia mielóide aguda |
| EP3362066B1 (en) | 2015-10-15 | 2021-10-06 | Les Laboratoires Servier SAS | Combination therapy for treating malignancies |
| US20200237881A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| EP3538135A4 (en) | 2016-11-11 | 2020-07-29 | Horizon Pharma Rheumatology LLC | POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| CN109207479A (zh) * | 2018-09-07 | 2019-01-15 | 大连大学 | 海洋低温尿酸氧化酶启动子和终止子 |
| WO2020160322A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple) |
| CN111088268B (zh) * | 2019-03-05 | 2022-08-02 | 北京锦篮基因科技有限公司 | 一种高尿酸血症的基因治疗药物 |
| KR102785972B1 (ko) * | 2019-05-10 | 2025-03-24 | 피이지-바이오 바이오팜 컴퍼니 리미티드 (총칭) | 폴리에틸렌 글리콜로 변형된 요산 산화효소 |
| EP4192581A4 (en) | 2020-08-10 | 2024-09-25 | Horizon Therapeutics USA, Inc. | METHODS OF TREATING GOUT |
| CN114438047B (zh) * | 2020-11-05 | 2024-11-22 | 重庆派金生物科技有限公司 | 制备聚乙二醇修饰的尿酸氧化酶的方法 |
| EP4321179A4 (en) * | 2021-05-07 | 2025-02-19 | Peking University | PROCESS FOR INITIATING POLYMERIZATION OF N-CARBOXYANHYDRIDES OF AMINO ACIDS IN AQUEOUS PHASE |
| CN113244412B (zh) * | 2021-06-25 | 2021-10-26 | 深圳市瑞吉生物科技有限公司 | 一种基于mRNA剂型的治疗高尿酸血症或痛风的药物及其制备方法 |
| PE20251580A1 (es) | 2022-06-03 | 2025-06-16 | Boehringer Ingelheim Int | Expresion recombinante del factor de crecimiento derivado de mieloides |
| AU2023390556A1 (en) * | 2022-12-08 | 2025-06-19 | Insmed Incorporated | Uricase conjugates and methods of use thereof |
| AU2024268255A1 (en) * | 2023-05-05 | 2025-11-13 | Insmed Incorporated | Uricase variants and methods of use thereof |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
| WO2025073372A1 (en) | 2023-10-05 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Recombinant expression of myeloid-derived growth factor |
| US20250186549A1 (en) | 2023-12-06 | 2025-06-12 | Boehringer Ingelheim International Gmbh | Novel formulation comprising myeloid-derived growth factor |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3451996A (en) * | 1968-02-12 | 1969-06-24 | Thompson Farms Co | Method for the preparation of heparin |
| US3616231A (en) * | 1968-11-14 | 1971-10-26 | Boehringer Mannheim Gmbh | Process for the production of uricase |
| US3931399A (en) * | 1970-12-22 | 1976-01-06 | Behringwerke Aktiengesellschaft | Process for isolating a fibrin-stabilizing factor |
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4169764A (en) * | 1975-08-13 | 1979-10-02 | Ajinomoto Co., Inc. | Process for production of urokinase |
| US4141973A (en) * | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
| US4301153A (en) * | 1977-03-21 | 1981-11-17 | Riker Laboratories, Inc. | Heparin preparation |
| US4425431A (en) * | 1978-04-20 | 1984-01-10 | Toyo Soda Manufacturing Co., Ltd. | Production of an allose-containing polysaccharide |
| US4312979A (en) * | 1978-04-20 | 1982-01-26 | Toyo Soda Manufacturing Co., Ltd. | Polysaccharides containing allose |
| JPS6031472B2 (ja) * | 1978-12-14 | 1985-07-22 | 協和醗酵工業株式会社 | 酸性ウリカ−ゼ |
| JPS5599189A (en) | 1979-01-22 | 1980-07-28 | Mihama Hisaharu | Modified uricase free from antigenicity and its preparation |
| DE2916711A1 (de) * | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
| FR2475900A1 (fr) * | 1980-02-20 | 1981-08-21 | Fabre Sa Pierre | Complexe vaccinal contenant un antigene specifique et vaccin le contenant |
| JPS5740503A (en) * | 1980-08-22 | 1982-03-06 | Seikagaku Kogyo Co Ltd | Separation of saccharides |
| FR2497006A1 (fr) | 1980-12-24 | 1982-06-25 | Ind Electro Ste Gle | Contacts electriques pour cables coaxiaux et cables bifilaires |
| DE3126759A1 (de) * | 1981-07-07 | 1983-01-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung |
| US4485176A (en) * | 1982-06-28 | 1984-11-27 | E. I. Du Pont De Nemours & Company | Turbidimetric method for measuring protein in urine and cerebrospinal fluid |
| EP0109688A3 (en) * | 1982-11-23 | 1986-12-03 | The Wellcome Foundation Limited | Improved complexes, processes for obtaining them and formulations containing such complexes |
| US4732863A (en) | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| JPH0671425B2 (ja) * | 1985-06-05 | 1994-09-14 | サッポロビール株式会社 | ウリカ−ゼおよびその製造法 |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4917888A (en) * | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| AU597924B2 (en) * | 1985-12-11 | 1990-06-14 | Natinco Nv | Solubilization of protein aggregates |
| DD279486A1 (de) | 1986-03-10 | 1990-06-06 | Akad Wissenschaften Ddr | Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen |
| JPS6255079A (ja) | 1986-04-23 | 1987-03-10 | Mihama Hisaharu | 修飾ウリカ−ゼ |
| AU612133B2 (en) * | 1987-02-20 | 1991-07-04 | Natinco Nv | Production of proteins in active forms |
| CA1305285C (en) * | 1987-04-21 | 1992-07-14 | Malcolm Roy Brandon | Production of proteins in active forms |
| AU609824B2 (en) * | 1987-06-15 | 1991-05-09 | Southern Cross Biotech Pty Ltd. | Production of proteins in active forms |
| US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| US4945086A (en) * | 1988-05-03 | 1990-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Smooth muscle cell growth inhibitor |
| US5955336A (en) * | 1988-08-17 | 1999-09-21 | Toyo Boseki Kabushiki Kaisha | DNA sequence for uricase and manufacturing process of uricase |
| US5349052A (en) * | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| US5324844A (en) * | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5010183A (en) * | 1989-07-07 | 1991-04-23 | Macfarlane Donald E | Process for purifying DNA and RNA using cationic detergents |
| KR0159107B1 (ko) * | 1989-07-13 | 1998-11-16 | 쟝 르쌍드뢰 | 우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포 |
| NZ234453A (en) | 1989-07-13 | 1993-01-27 | Sanofi Sa | Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith |
| US5286637A (en) * | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
| CA2065744A1 (en) * | 1989-08-23 | 1991-02-24 | Zvi Fuks | Wound healing preparations containing heparanase |
| JPH03148298A (ja) | 1989-11-01 | 1991-06-25 | Sumitomo Pharmaceut Co Ltd | 修飾ペプチドおよびその製造方法 |
| US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5653974A (en) * | 1990-10-18 | 1997-08-05 | Board Of Regents,The University Of Texas System | Preparation and characterization of liposomal formulations of tumor necrosis factor |
| ES2141108T3 (es) * | 1991-07-02 | 2000-03-16 | Inhale Inc | Metodo y dispositivo para proporcionar medicamentos en aerosol. |
| YU66892A (sh) | 1991-08-20 | 1995-10-24 | Hoechst Ag. | Fosfoinositolglikan - peptid sa delovanjem kao insulin |
| US5298643A (en) * | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
| US5321095A (en) * | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
| WO1994019007A1 (en) | 1993-02-16 | 1994-09-01 | Enzon, Inc. | Ribosome inactivating protein compositions having reduced antigenicity |
| US6385312B1 (en) * | 1993-02-22 | 2002-05-07 | Murex Securities, Ltd. | Automatic routing and information system for telephonic services |
| JP3875730B2 (ja) | 1993-02-22 | 2007-01-31 | サノフィ・アベンティス株式会社 | 自己免疫疾患の予防治療剤 |
| US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
| WO1994023735A1 (en) | 1993-04-09 | 1994-10-27 | Bio-Technology General Corp. | Novel polypeptide having factor xa inhibitory activity |
| WO1995000162A1 (en) * | 1993-06-21 | 1995-01-05 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
| US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| EP0730660A4 (en) | 1993-10-29 | 1998-02-25 | Incyte Pharma Inc | CHIMEAN PROTEINE PROTEASE NEXIN-1 CONTAINING VARIANTS |
| US5795776A (en) | 1994-03-22 | 1998-08-18 | Bio-Technology General Corp. | Expression plasmids regulated by an OSMB promoter |
| FI96317C (fi) * | 1994-05-31 | 1996-06-10 | Exavena Oy | Menetelmä hienojakoisten ja muunnettujen tärkkelyksien valmistamiseksi |
| DE4423131A1 (de) * | 1994-07-01 | 1996-01-04 | Bayer Ag | Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4 |
| US5633227A (en) * | 1994-09-12 | 1997-05-27 | Miles, Inc. | Secretory leukocyte protease inhibitor as an inhibitor of tryptase |
| FI972443A0 (fi) * | 1994-12-07 | 1997-06-09 | Novo Nordisk As | Polypeptidi, jonka allergeenisuus on vähentynyt |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| IL116696A (en) | 1995-01-25 | 1999-08-17 | Bio Technology General Corp | Production of enzymatically active recombinant carboxypeptidase b |
| FR2733914B1 (fr) * | 1995-05-11 | 1997-08-01 | Sanofi Sa | Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation |
| JPH09154581A (ja) | 1995-12-05 | 1997-06-17 | Asahi Chem Ind Co Ltd | ウリカーゼを生産する実質上純粋な微生物 |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| AU725133B2 (en) | 1997-01-15 | 2000-10-05 | Polaris Group | Modified tumor necrosis factor |
| KR100369838B1 (ko) | 1997-02-26 | 2003-09-29 | 주식회사 엘지생명과학 | 한국형c형간염바이러스의비구조단백질3에서유래한단백질분해효소단백질및그의제조방법 |
| JPH1175876A (ja) * | 1997-07-04 | 1999-03-23 | Ajinomoto Co Inc | 新規な微生物トランスグルタミナーゼの製造法 |
| IL139609A (en) * | 1998-06-01 | 2006-06-11 | Genentech Inc | Separation of polypeptides monomers |
| EP2316475B1 (en) * | 1998-08-06 | 2017-10-04 | Mountain View Pharmaceuticals, Inc. | Isolated tetrameric uricase |
| PL202799B1 (pl) * | 1998-08-06 | 2009-07-31 | Mountain View Pharmaceuticals | Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza |
| US6783965B1 (en) * | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| RU2290439C2 (ru) | 1998-08-06 | 2006-12-27 | Дьюк Юниверсити | Рекомбинантный белок уриказы млекопитающего для конъюгирования с пэг, молекула нуклеиновой кислоты, кодирующая его, вектор для его экспрессии, способ его получения и применение |
| US6429860B1 (en) * | 1999-06-15 | 2002-08-06 | Visicomp, Inc. | Method and system for run-time visualization of the function and operation of a computer program |
| RU2286711C2 (ru) * | 2000-02-14 | 2006-11-10 | Фёрст Опинион Корпорэйшн | Система и способ автоматической диагностики |
| US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| AU2002365360A1 (en) | 2001-11-28 | 2003-06-10 | Biopolymed Inc. | Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same |
| US20080159976A1 (en) * | 2005-04-11 | 2008-07-03 | Jacob Hartman | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| PL3321359T3 (pl) * | 2005-04-11 | 2021-06-28 | Horizon Pharma Rheumatology Llc | Wariantowe postacie oksydazy moczanowej i ich zastosowanie |
| US8148123B2 (en) * | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| EP2013225B1 (en) * | 2006-04-12 | 2014-12-17 | Crealta Pharmaceuticals LLC | Purification of proteins with cationic surfactant |
-
2006
- 2006-04-11 TW TW095112941A patent/TW200716751A/zh unknown
- 2006-04-11 BR BRPI0612942-0A patent/BRPI0612942A2/pt not_active Application Discontinuation
- 2006-04-11 EP EP06740863A patent/EP1871877A2/en not_active Ceased
- 2006-04-11 KR KR1020077026114A patent/KR101304289B1/ko active Active
- 2006-04-11 JP JP2008505656A patent/JP2008535499A/ja active Pending
- 2006-04-11 AU AU2006235437A patent/AU2006235437B2/en active Active
- 2006-04-11 CZ CZ20070700A patent/CZ2007700A3/cs unknown
- 2006-04-11 CN CN2012102463263A patent/CN102807973A/zh active Pending
- 2006-04-11 SG SG10201706384VA patent/SG10201706384VA/en unknown
- 2006-04-11 CN CN2006800206898A patent/CN101194016B/zh active Active
- 2006-04-11 WO PCT/US2006/013502 patent/WO2006110761A2/en not_active Ceased
- 2006-04-11 EP EP14192835.8A patent/EP2918676B1/en active Active
- 2006-04-11 MX MX2007012548A patent/MX2007012548A/es active IP Right Grant
- 2006-04-11 NZ NZ562291A patent/NZ562291A/en unknown
- 2006-04-11 SG SG201002408-1A patent/SG161248A1/en unknown
- 2006-04-11 HU HU0700729A patent/HU229626B1/hu unknown
- 2006-04-11 SG SG2014009484A patent/SG2014009484A/en unknown
- 2006-04-11 PL PL384263A patent/PL215157B1/pl unknown
- 2006-04-11 RU RU2007141683/10A patent/RU2435847C2/ru active
- 2006-04-11 US US11/918,296 patent/US7811800B2/en active Active
- 2006-04-11 CA CA002604545A patent/CA2604545A1/en not_active Abandoned
-
2007
- 2007-10-09 IL IL186511A patent/IL186511A/en active IP Right Grant
-
2010
- 2010-09-10 US US12/879,084 patent/US7964381B2/en active Active
- 2010-10-12 IL IL208643A patent/IL208643A0/en active IP Right Grant
-
2011
- 2011-05-13 US US13/107,498 patent/US8034594B2/en active Active
- 2011-09-07 US US13/226,891 patent/US8178334B2/en active Active
-
2012
- 2012-04-20 US US13/452,151 patent/US8293228B2/en active Active
- 2012-09-20 US US13/623,512 patent/US8465735B2/en active Active
- 2012-12-06 IL IL223476A patent/IL223476A/en active IP Right Grant
- 2012-12-06 IL IL223477A patent/IL223477A/en active IP Right Grant
-
2013
- 2013-01-23 JP JP2013009960A patent/JP2013090636A/ja not_active Withdrawn
-
2015
- 2015-01-07 JP JP2015001757A patent/JP2015077144A/ja not_active Withdrawn
-
2017
- 2017-12-06 IL IL256157A patent/IL256157B/en active IP Right Grant
-
2021
- 2021-03-03 IL IL281228A patent/IL281228A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007141683A (ru) | Вариантная форма урат-оксидазы и ее использование | |
| RU2012106148A (ru) | Вариантные формы уратоксидазы и их применение | |
| DK1885850T3 (da) | Fremgangsmåde til fremstilling af D-psicose ved D-psicose-epimerase | |
| HRP20201185T1 (hr) | Gdf zamke | |
| DK2041276T3 (da) | Fremgangsmåde til fremstilling af l-aminosyrer ved hjælp af mutanter af glta-genet kodende for citrat synthase | |
| IN2014CN02050A (ru) | ||
| JP2007175057A5 (ru) | ||
| UA94019C2 (ru) | Антитело, которое специфически связывается с глипиканом 3 (gpc3) | |
| NZ580378A (en) | Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells | |
| RU2014145441A (ru) | Векторы | |
| RU2010108308A (ru) | Способ получения гетерогенных белков | |
| GB201201178D0 (en) | Novel enzymes | |
| RU2009148322A (ru) | Новые гены ацилтрансферазы лизофосфатидной кислоты | |
| WO2008005880A3 (en) | Antibodies for norovirus | |
| RU2011142793A (ru) | Полученная из микроорганизма протеаза усовершенствованного типа, обеспечивающая свертывание молока | |
| RU2014144881A (ru) | Способ экспрессии полипептидов с применением модифицированных нуклеиновых кислот | |
| ATE546464T1 (de) | Verfahren zur produktion von rekombinantem protein in cho-zellen | |
| RU2016152429A (ru) | Меченый антиген е гепаднавируса и его применение в скрининге противовирусных веществ | |
| NZ590011A (en) | Chloramphenicol acetyl transferase (cat)-defective somatostatin fusion protein and uses thereof | |
| RU2012121884A (ru) | Варианты вируса гепатита с | |
| TW200638944A (en) | Recombinant enterovirus 71 neutralizing antibodies and use thereof | |
| WO2010140388A3 (en) | Gene for increasing plant weight and method for using the same | |
| ATE445009T1 (de) | Signalpeptid zur herstellung eines polypeptids | |
| WO2008002548A3 (en) | Novel human acidic mammalian chitinase and use thereof | |
| RU2004139054A (ru) | Модифицированные фитазы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20141209 |